Scott R. Plotkin

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 22 papers. Top paper: “Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial”.

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Blood(2022)10.1182/blood.2021014738

N/A

4.5DataRank · unranked

141 citations

Jörg Dietrich, Kathleen Gallagher, Mark Roschewski, Justin T. Jordan, Deborah Forst +22 more

Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial

Nature Medicine(2021)10.1038/s41591-020-01193-6

N/A

2.0DataRank · unranked

96 citations

Chie‐Schin Shih, Steven D. Rhodes, Amy E. Armstrong, Pamela L. Wolters, Eva Dombi +25 more

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Genetics in Medicine(2022)10.1016/j.gim.2022.05.007

N/A

0.846DataRank · unranked

281 citations

Ludwine Messiaen, Eric Legius, Patrice Pancza, Robert A. Avery, Jaishri O. Blakeley +79 more

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2225

N/A

0.644DataRank · unranked

72 citations

Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek Walenkamp, Adam L. Green +13 more

Identifying challenges in neurofibromatosis: a modified Delphi procedure

European Journal of Human Genetics(2021)10.1038/s41431-021-00892-z

N/A

0.396DataRank · unranked

13 citations

Rosalie E. Ferner, Annette Bakker, Marco Nievo, D. Gareth Evans, P. Wolkenstein +6 more

Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2024

N/A

0.345DataRank · unranked

9 citations

Priya Kumthekar, Patrick Y. Wen, Frederick G. Barker, Anat Stemmer‐Rachamimov, Roberta L. Beauchamp +4 more

Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

Neuro-Oncology Advances(2024)10.1093/noajnl/vdae202

N/A

0.345DataRank · unranked

9 citations

Adam L. Cohen, Midori Eckenstein, Randy L. Jensen, Lindsay Burt, Karen L. Salzman +18 more

Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.06.527377

N/A

0.307DataRank · unranked

5 citations

Limeng Wu, Yanling Zhang, Yao Sun, John W. Chen, Sonu Subudhi +15 more

Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models

Neuro-Oncology Advances(2024)10.1093/noajnl/vdae024

N/A

0.241DataRank · unranked

4 citations

Janet L. Oblinger, Roberta L. Beauchamp, Lili Kosa, Françis Robert, Scott R. Plotkin +3 more

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma

Neuro-Oncology(2025)10.1093/neuonc/noaf287

N/A

0.241DataRank · unranked

4 citations

Elisa Aquilanti, Julie J. Miller, Zhou Lan, Aleksandra B Lasica, Isabel Arrillaga‐Romany +20 more

Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration

Clinical Trials(2023)10.1177/17407745231201345

N/A

0.165DataRank · unranked

2 citations

Andrea M. Gross, Brigitte C. Widemann, Scott R. Plotkin, Vanessa L. Merker

Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma

Neuro-Oncology(2023)10.1093/neuonc/noad037

N/A

0DataRank · unranked

10 citations

Janet L. Oblinger, Roberta L. Beauchamp, Zhenzhen Yin, Serkan Erdin, Priya Koundinya +8 more

Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0143

N/A

0DataRank · unranked

23 citations

Audrey Mauguen, Ekrem Maloku, Qingwen Xu, Erin Dunbar, Scott R. Plotkin +17 more

Awareness and Agreement with Neurofibromatosis Care Guidelines among Neurofibromatosis Specialists

medRxiv(2021)10.1101/2021.06.16.21259047

N/A

0DataRank · unranked

0 citations

Pamela Knight, Heather B. Radtke, Kaleb Yohay, Nicole J. Ullrich, Scott R. Plotkin +2 more

Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care

The Oncologist(2022)10.1093/oncolo/oyac069

N/A

0DataRank · unranked

18 citations

Naomi Y. Ko, Elizabeth Paige Walsh, Veronica Decker, Isabel Arrillaga‐Romany, Scott R. Plotkin +4 more

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

medRxiv(2022)10.1101/2022.03.31.22273208

N/A

0DataRank · unranked

0 citations

Jan M. Friedman, Laura J. Klesse, Kaleb Yohay, Justin T. Jordan, Scott R. Plotkin +3 more

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

Journal of Biological Chemistry(2020)10.1074/jbc.ra120.014960

N/A

0DataRank · unranked

18 citations

Serkan Erdin, Luke Witt, Justin T. Jordan, Scott R. Plotkin, James F. Gusella +2 more

Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials

Clinical Trials(2023)10.1177/17407745231178839

N/A

0DataRank · unranked

6 citations

Kavita Y. Sarin, Andrea Petersen, Dominique C. Pichard, Pamela L. Wolters, Gregg Erickson +8 more

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1

Clinical Trials(2023)10.1177/17407745231201338

N/A

0DataRank · unranked

1 citations

Scott R. Plotkin, Nelson B. Watts, Michael J. Fisher, Laura J. Klesse, Andrés J Lessing +9 more

Evolving concepts in meningioma management in the era of genomics

Cancer(2024)10.1002/cncr.35279

N/A

0DataRank · unranked

12 citations

Wenya Linda Bi, Vijaya Ramesh, Priscilla K. Brastianos, Scott R. Plotkin, Annie L. Hsieh

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis

Cancers(2024)10.3390/cancers16111961

N/A

0DataRank · unranked

4 citations

Zhenzhen Yin, Jie Chen, Limeng Wu, Yao Sun, Xing Gao +5 more

Expanding therapeutic options for people with NF2-related schwannomatosis: Encouraging results with brigatinib

Neuro-Oncology(2024)10.1093/neuonc/noae137

N/A

0DataRank · unranked

3 citations

Jaishri O. Blakeley, Scott R. Plotkin